FIELDS H-l and H-2 

 Columns 29, 30, 31, 

 32, 33, and 34 



that is host to a tumor, noninfectious pathological condition, or parasitic organism, the anatomical 

 entries of Fields H-l, H-2, and I always are structures of that host. (This was explained above in 

 the second paragraph of this Section on General Use. ) THIS SITE OF A TUMOR OR PATHOLOGY IS 

 ALWAYS CODED IN FIELD H-l, with certain exceptions for special infrequently occurring situations 

 explained in Division 6 of the section on Specific Directions and Explanations below. (Even for such 

 an exception, however, when the site of a pathology is by necessity entered in Field H-2 instead of 

 Field H-l, the fact of the transfer of the entry to Field H-2 is always clearly indicated in Field H-l 

 by the Symbol * [the IBM 12 zone punch] being used in Column 30. ) 



Specific Directions and Explanations 



1. Distinction between uses of Fields H-l and H-2 



This is discussed in the previous section on General Use. In summary, Field H- 1 is used for 

 recording the primary organ, i. e. , (1) the organ actually treated and acted upon by the test compound 

 or the organ in which the test observation for response was made, or (2) the organ in which a tumor, 

 non-infectious pathology, or parasitic organism was experimentally treated. Field H-2 is used to 

 record organs other than the primary organ: (1) an organ other than the primary organ, specially 

 modified; (2) an organ, other than the primary organ, to which the test compound was applied (when 

 application was not directly to the primary organ), or (3) (rarely, and with an asterisk coded in 

 Column 30 of Field H-l) an organ in which a pathology was treated (coded in Field E), when the response 

 and observation was actually on an organ other than the organ most specifically affected by the pathology 

 (see the example given in the last paragraph of Division 6 below). 



2. Use of Field H-2 to supplement coding in Field S-3; a specific organ or body area at which 

 application is made when it is not the responding organ or body area in Field H-l 



In Field S-3 is coded the route of administration of a test compound. The descriptions of these 

 routes often include designations of a specific anatomical structure to which or through which appli- 

 cation is made. However, certain routes, as defined in Field S-3, are somewhat general, without 

 specifying a structure (e. g. , intravascular, or in an exposed organ, or topical, etc. --without specifying 

 which blood vessel, organ, body area, etc. , is actually treated). Since the specific organ or body area 

 to which application is made is sometimes significant and indicated by the author, Field H is used with 

 Field S-3 for coding it. If the administration (described in Field S-3) is directly to the organ which is 

 the responding organ (in Field H-l), the responding organ and the organ to which application is made 

 are identical and are both indicated by the identical entry in Field H-l. However, if administration is 

 applied at a site other than the responding organ in Field H-l, this difference between the application 

 site and the site of response must be recorded in Field S-3, both by code and by a written abstract. 

 In coding this difference, it is necessary to supplement Field S-3 by designating a site of application 

 (other than the responding organ in Field H-l) more specifically than the Field S-3 symbol is capable 

 of doing, and for this Field H-2 is used. Field H-2 is used to supplement the following symbols of 

 Field S-3: 3, 4, 5, 7, 8, B, C, D, E, F, G, I, 0, P, S, and Z. None of the other symbols (0, 1, 2, 

 6, 9, A, H, J, K, L, M, N, Q, R, T, U, V, W, X, and Y) need to be supplemented by coding in 

 Field H-2. 



The following division explains how an entry in Field H-2 must be coded and subsequently 

 interpreted relative to Field S-3 and Fields G-l and G-2 and L. It also explains that there would be 

 some advantage to having a special field for supplementing coding of Field S-3, since Field H-2 can 

 only be used for this purpose when it is not occupied with organs related to coding in Field G or L or 

 Column 30 of Field H-l. The latter coding areas must be examined before it can be certain that coding 

 in Field H-2 relates to Field S-3. 



3. Conflicts in Field H-2 due to its multiple uses; order of preference in use 



The fields most especially related to Field H-2 may be regarded as two groups, (1) Fields G-l, 

 G-2, and L, and (2) Field S-3, whose relationships to Field H-2 represent two distinct uses for 

 Field H-2. There would be advantages in having three fields, each comparable to Field H-2--one for 

 organs specially modified (Fields G-l, G-2, and L) and one for organs to which the test compound was 



- 60 



